NICE says it can approve BioMarin's ultra-rare drug treatment Vimizim, but has proposed real-world data collection and a price cap to overcome doubts about the drug's value, reports Andrew McConaghie.
In 2015, NICE said that BioMarin's Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected on its efficacy. Now – almost seven ...
LONDON, GREATER LONDON, UNITED KINGDOM, March 14, 2025 /EINPresswire / -- How Is the Vimizim Elosulfase Alfa Market Poised for Significant Expansion? Recent trends indicate a notable compound ...